Anti-A1AT/ SERPINA1/ A1A functional antibody
Anti-A1AT/ SERPINA1/ A1A functional antibody for cell culture, ELISA & in-vivo assay
Go to SERPINA1/SERPINA1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T28265-Ab-1/ GM-Tg-hg-T28265-Ab-2 | Anti-Human SERPINA1 monoclonal antibody | Human |
GM-Tg-rg-T28265-Ab-1/ GM-Tg-rg-T28265-Ab-2 | Anti-Rat SERPINA1 monoclonal antibody | Rat |
GM-Tg-mg-T28265-Ab-1/ GM-Tg-mg-T28265-Ab-2 | Anti-Mouse SERPINA1 monoclonal antibody | Mouse |
GM-Tg-cynog-T28265-Ab-1/ GM-Tg-cynog-T28265-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SERPINA1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T28265-Ab-1/ GM-Tg-felg-T28265-Ab-2 | Anti-Feline SERPINA1 monoclonal antibody | Feline |
GM-Tg-cang-T28265-Ab-1/ GM-Tg-cang-T28265-Ab-2 | Anti-Canine SERPINA1 monoclonal antibody | Canine |
GM-Tg-bovg-T28265-Ab-1/ GM-Tg-bovg-T28265-Ab-2 | Anti-Bovine SERPINA1 monoclonal antibody | Bovine |
GM-Tg-equg-T28265-Ab-1/ GM-Tg-equg-T28265-Ab-2 | Anti-Equine SERPINA1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T28265-Ab-1/ GM-Tg-hg-T28265-Ab-2; GM-Tg-rg-T28265-Ab-1/ GM-Tg-rg-T28265-Ab-2; GM-Tg-mg-T28265-Ab-1/ GM-Tg-mg-T28265-Ab-2; GM-Tg-cynog-T28265-Ab-1/ GM-Tg-cynog-T28265-Ab-2; GM-Tg-felg-T28265-Ab-1/ GM-Tg-felg-T28265-Ab-2; GM-Tg-cang-T28265-Ab-1/ GM-Tg-cang-T28265-Ab-2; GM-Tg-bovg-T28265-Ab-1/ GM-Tg-bovg-T28265-Ab-2; GM-Tg-equg-T28265-Ab-1/ GM-Tg-equg-T28265-Ab-2 |
Products Name | Anti-SERPINA1 monoclonal antibody |
Format | mab |
Target Name | SERPINA1 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-SERPINA1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T28265-Ag-1 | Recombinant multi-species A1AT/ SERPINA1/ A1A protein |
ORF Viral Vector | vGMLP003894 | human SERPINA1 Lentivirus particle |
ORF Viral Vector | pGMLP003894 | human SERPINA1 Lentivirus plasmid |
ORF Viral Vector | vGMAP000441 | Human SERPINA1 Adenovirus particle |
ORF Viral Vector | pGMAP000441 | Human SERPINA1 Adenovirus plasmid |
ORF Viral Vector | pGMAAV000168 | human SERPINA1 AAV plasmid |
ORF Viral Vector | vGMAAV000168 | human SERPINA1 AAV particle |
ORF Viral Vector | pGMLPm003774 | mouse Serpina1c Lentivirus plasmid |
ORF Viral Vector | vGMLPm003774 | mouse Serpina1c Lentivirus particle |
Target information
Target ID | GM-T28265 |
Target Name | SERPINA1 |
Gene ID | 5265,701361,280699 |
Gene Symbol and Synonyms | A1A,A1AT,AAT,alpha1AT,nNIF,PI,PI1,PRO2275,SERPINA1 |
Uniprot Accession | P01009,P34955 |
Uniprot Entry Name | A1AT_HUMAN,A1AT_BOVIN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Therapeutics Target |
Disease | Malignant neoplasm of bladder, IgA glomerulonephritis, Nephrotic syndrome with focal and segmental glomerular lesions, Diabetic Nephropathy, Contrast - Induced Nephropathy, Congenital occlusion of ureteropelvic junction, Calculus of kidney, Nephrotic syndrome, Acute pancreatitis, Juvenile arthritis, Urinary bladder urothelial carcinoma, Type 2 diabetes mellitus with diabetic nephropathy, protease |
Gene Ensembl | ENSG00000197249 |
Target Classification | N/A |
The target: SERPINA1, gene name: SERPINA1, also named as A1A, A1AT, AAT, PI, PI1, PRO2275, alpha1AT, nNIF. The protein encoded by this gene is a serine protease inhibitor belonging to the serpin superfamily whose targets include elastase, plasmin, thrombin, trypsin, chymotrypsin, and plasminogen activator. This protein is produced in the liver, the bone marrow, by lymphocytic and monocytic cells in lymphoid tissue, and by the Paneth cells of the gut. Defects in this gene are associated with chronic obstructive pulmonary disease, emphysema, and chronic liver disease. Several transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Aug 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.